2025

Alex's Lemonade Stand Foundation

Lymphoma Impact Report

AlexsLemonade.org

Alex's Lemonade Stand Foundation (ALSF) emerged from the front yard lemonade stand of 4-year-old Alexandra “Alex” Scott, who was fighting cancer and wanted to raise money to find cures for all children with cancer. By the time Alex passed away at the age of 8, she had raised $1 million. Since then, the Foundation bearing her name has evolved into a worldwide fundraising movement and the largest independent childhood cancer charity in the U.S. ALSF is a leader in funding pediatric cancer research projects across the globe and providing programs to families affected by childhood cancer.

With Gratitude

Dear Friend,

All of us at Alex's Lemonade Stand Foundation are sending a heartfelt thank you for supporting Alex's mission of curing childhood cancers like lymphoma through the discovery of new and safer treatments.

Your generosity empowers scientists to gather crucial preliminary data, publish breakthrough findings, and advance innovative treatment approaches. Because of you, we're moving closer to a future where no child faces lymphoma.

It's an honor to stand beside you in this fight. Your commitment fuels life-saving progress. If there's ever anything we can do for you, please let the ALSF team know.

Until there are cures,

Liz & Jay Scott
Alex's Parents & Co-Executive Directors
Alex's Lemonade Stand Foundation

ALSF

Thanks to Supporters Like You

20 **Lymphoma projects (and counting) have been funded**

"ALSF funding was absolutely essential to make this project happen. There are not many funding instruments available to support projects of this scale."

— Dr. Florian Halbritter,
St. Anna Children's Cancer Research Institute

"Early career support for pediatric oncology physician-scientists is a critical lifeline during an incredibly vulnerable time in our careers. The support of ALSF has been and continues to be absolutely essential in making better therapies available faster for pediatric cancer patients."

— Dr. Leo Wang,
City of Hope

ALSF

Meet a **Lymphoma Hero**



Name: Lexi
Loves: Water Color, Softball, Volleyball, and Basketball

Seven-year-old Lexi came home from basketball practice one afternoon complaining that it hurt to breathe. What her pediatrician first chalked up to a seasonal virus soon spiraled into 104-degree fevers, crushing fatigue, and three anxiety-filled weeks of inconclusive labs. When a sleepless night left Lexi gasping for air, her mom, Kayci, insisted on a CT scan. The images lit up with swollen lymph nodes and a biopsy confirmed every parent's nightmare: anaplastic large-cell lymphoma (ALCL).

Lexi began 18 rounds of chemotherapy at Children's Mercy Hospital in Kansas City. Treatment pushed the cancer into remission, until a routine scan later detected a relapse. Eight additional weeks of high-dose chemo and a bone-marrow transplant followed.

Through every needle stick and scan, Lexi never cried. Her family is proud of the way she never gives up. Today, Lexi juggles basketball, softball and volleyball, but in her downtime loves to paint and draw.

Survivorship has become stewardship for the Wilsons. They run lemonade stands during Midwest Lemonade Days and participating in childhood cancer day at the Kansas City Royals game, channeling every dollar to ALSF. Her family is so glad to see ALSF show the same dedication to helping kids like Lexi, as Lexi shows in everything she does.

> "I beat cancer twice. Could you even tell?"
>
> – Lexi

ALSF

Research Spotlight: New Projects in Lymphoma

Towards LNP Vaccine Immune-Interception for Childhood Cancer Predisposition Syndromes

Uri Tabori, MD, The Hospital for Sick Children (SickKids)

Some children inherit genetic syndromes such as Li-Fraumeni or mismatch repair deficiency. These genetic syndromes put children at an extremely high risk of developing cancer. These cancers are often resistant to standard treatments, making prevention especially important. Dr. Uri Tabori and Dr. David Malkin at The Hospital for Sick Children in Toronto are exploring a groundbreaking idea: using a personalized cancer vaccine to stop and block cancer before it even starts. Their research focuses on “immune interception,” teaching the immune system to recognize and eliminate early cancer cells by targeting unique mutated proteins known as neoantigens. Using mRNA technology, they hope to prevent tumor development all together. If successful, this approach could revolutionize and change the future of care for children with cancer predisposition syndromes and potentially extend to even more pediatric cancers.

Exploring the interplay of microbiome, bile acids, immune reconstitution, and clinical outcomes following allogeneic hematopoietic transplantation

Hannah Gulko, Memorial Sloan-Kettering Cancer Center

The gut microbiome plays a critical role in modulating the immune response, influencing outcomes of allogeneic transplantation, a life-saving treatment for relapsed/refractory leukemia and lymphoma. However, this treatment comes with significant complications that can limit its efficacy. Understanding and leveraging the immunomodulatory potential of the microbiome is crucial for optimizing cancer therapy outcomes. However, the mechanisms underlying the microbiome's influence on outcomes post-transplant, especially in pediatric patients, remain insufficiently understood. The proposed project aims to unravel the intricate relationship between the microbiome, bile acids, and allogeneic hematopoietic transplantation outcomes in pediatric recipients.





Thank You

for all you do to help kids with cancer!